Patents by Inventor Shahul Nilar

Shahul Nilar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS
    Publication number: 20250109122
    Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I? and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
    Type: Application
    Filed: November 21, 2024
    Publication date: April 3, 2025
    Inventors: QING XU, CARSTEN ALT, ZHE LI, SHAHUL NILAR, PETER MICHAEL RADEMACHER, CALVIN WESLEY YEE
  • Cycloalkyl pyrimidines as ferroportin inhibitors
    Patent number: 12202817
    Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I? and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
    Type: Grant
    Filed: June 15, 2023
    Date of Patent: January 21, 2025
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Qing Xu, Carsten Alt, Zhe Li, Shahul Nilar, Peter Michael Rademacher, Calvin Wesley Yee
  • LACTAM PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS
    Publication number: 20240408107
    Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
    Type: Application
    Filed: October 5, 2022
    Publication date: December 12, 2024
    Applicant: Global Blood Therapeutics, Inc.
    Inventors: Shahul Nilar, Lina Q. Setti, Chul Yu, Ming Yu
  • CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS
    Publication number: 20240140932
    Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I? and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
    Type: Application
    Filed: June 15, 2023
    Publication date: May 2, 2024
    Inventors: QING XU, CARSTEN ALT, ZHE LI, SHAHUL NILAR, PETER MICHAEL RADEMACHER, CALVIN WESLEY YEE
  • UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS
    Publication number: 20230278984
    Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
    Type: Application
    Filed: August 3, 2021
    Publication date: September 7, 2023
    Inventors: Lina Q. Setti, Brian Cathers, Zhe Li, Shahul Nilar, James Partridge, Chul Yu, Ming Yu, Manuel Zancanella
  • Cycloalkyl pyrimidines as ferroportin inhibitors
    Patent number: 11746100
    Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I? and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: September 5, 2023
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Qing Xu, Carsten Alt, Zhe Li, Shahul Nilar, Peter Michael Rademacher, Calvin Wesley Yee
  • THIENO PYRIMIDINES AS FERROPORTIN INHIBITORS
    Publication number: 20230159553
    Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
    Type: Application
    Filed: April 28, 2021
    Publication date: May 25, 2023
    Inventors: Qing Xu, Zhe Li, Shahul Nilar
  • PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS
    Publication number: 20230151016
    Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
    Type: Application
    Filed: January 17, 2023
    Publication date: May 18, 2023
    Inventors: Lina Q. Setti, Shahul Nilar, Zhe Li, Ming Yu, Manuel Zancanella
  • Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
    Patent number: 11566030
    Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I: and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
    Type: Grant
    Filed: February 7, 2022
    Date of Patent: January 31, 2023
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Lina Q. Setti, Shahul Nilar, Zhe Li, Ming Yu, Manuel Zancanella
  • CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS
    Publication number: 20220396562
    Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I? and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
    Type: Application
    Filed: April 28, 2021
    Publication date: December 15, 2022
    Inventors: Qing Xu, CARSTEN ALT, ZHE LI, SHAHUL NILAR, PETER MICHAEL RADEMACHER, CALVIN WESLEY YEE
  • PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS
    Publication number: 20220267337
    Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.
    Type: Application
    Filed: February 7, 2022
    Publication date: August 25, 2022
    Inventors: Lina Q. Setti, Shahul Nilar, Zhe Li, Ming Yu, Manuel Zancanella
  • NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
    Publication number: 20080249131
    Abstract: Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.
    Type: Application
    Filed: May 2, 2008
    Publication date: October 9, 2008
    Applicant: Ardea Biosciences, Inc.
    Inventors: Jean-Luc Girardet, Zhijun Zhang, Robert Hamatake, Martha A. De La Rosa, Esmir Gunic, Zhi Hong, Hong Woo Kim, Yung-hyo Koh, Shahul Nilar, Stephanie Shaw, Nanhua Yao
  • Non-nucleoside reverse transcriptase inhibitors
    Publication number: 20060135556
    Abstract: Various carbonyl amides are employed in vitro and in vivo as non-nucleoside inhibitors of a reverse transcriptase, and particularly of HIV reverse transcriptase. Therefore, contemplated compounds may be employed in the treatment of HIV infected patients. Further contemplated aspects include pharmaceutical compositions comprising therapeutically effective amounts of contemplated compounds.
    Type: Application
    Filed: August 22, 2003
    Publication date: June 22, 2006
    Inventors: Jean-Luc Girardet, Zhijun Zhang, Robert Hamatake, Martha de la Rosa, Esmir Gunic, Zhi Hong, Hong Kim, Yung-Hyo Koh, Shahul Nilar, Stephanie Shaw, Nanhua Yao
  • Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
    Patent number: 6906190
    Abstract: A polymerase inhibitor has first moiety coupled to a second moiety via an optional linker in which the first moiety binds to an initiation nucleotide binding site of a polymerase and forms at least two hydrogen bonds with an RNA template strand that is associated with the polymerase, and in which the second moiety comprised a compound that binds to a site proximal to the nucleotide binding site of the polymerase and thereby increases the affinity of the polymerase inhibitor to the polymerase.
    Type: Grant
    Filed: December 27, 2002
    Date of Patent: June 14, 2005
    Assignee: Ribapharm Inc.
    Inventors: Nanhua Yao, Haoyun An, Todd Appleby, Shahul Nilar, Yili Ding, Zhi Hong
  • Inhibitors for de novo-RNA polymerases and methods of identifying targets for same
    Publication number: 20030187000
    Abstract: A polymerase inhibitor has first moiety coupled to a second moiety via an optional linker in which the first moiety binds to an initiation nucleotide binding site of a polymerase and forms at least two hydrogen bonds with an RNA template strand that is associated with the polymerase, and in which the second moiety comprised a compound that binds to a site proximal to the nucleotide binding site of the polymerase and thereby increases the affinity of the polymerase inhibitor to the polymerase.
    Type: Application
    Filed: December 27, 2002
    Publication date: October 2, 2003
    Inventors: Nanhua Yao, Haoyun An, Todd Appleby, Shahul Nilar, Yili Ding, Zhi Hong